Resistance to targeted therapies in breast cancer /

Saved in:
Bibliographic Details
Imprint:Cham, Switzerland : Springer, [2017]
©2017
Description:1 online resource
Language:English
Series:Resistance to targeted anti-cancer therapeutics, 2196-551X ; volume 16
Resistance to targeted anti-cancer therapeutics ; v. 16.
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11399447
Hidden Bibliographic Details
Other authors / contributors:Prosperi, Jenifer R., editor.
ISBN:9783319701424
3319701428
331970141X
9783319701417
9783319701417
Digital file characteristics:text file PDF
Notes:Includes bibliographical references and index.
Online resource; title from PDF title page (EBSCO, viewed December 14, 2017).
Summary:We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. #xE000.
Other form:Printed edition: 9783319701417
Standard no.:10.1007/978-3-319-70142-4